Company | Acquired By | Date | Date | Value | Terms/Details |
Acquired** | Or Merged With | Announced | Completed | (M) | |
(Country) | (Country) | ||||
I. COMPLETED MERGERS AND ACQUISITIONS | |||||
ACT Gene SA* | Visible Genetics | — | 4/98 | $1.3 | Visible Genetics acquired ACT |
(France) | Inc. (Canada) | Gene for US$0.45M plus 0.085M | |||
shares Visible Genetics common | |||||
stock (US$0.84) | |||||
Acute Therapeutics | Discovery | 2/98 | 6/98 | ND | Letter of intent dated 2/98; defini- |
Inc.* (majority-owned | Laboratories Inc. | tive agreement dated 3/98; Discov- | |||
subsidiary of Discovery | ery Labs acquired all outstand- | ||||
Laboratories Inc.) | ing shares of Acute Therapeutics | ||||
by issuing 3.90 shares for each | |||||
share Acute Therapeutics; the new | |||||
company will move to Acute Ther- | |||||
apeutics' headquarters and be run | |||||
by Acute Therapeutics' management | |||||
Anawa Holdings* | Phoenix | — | 5/98 | $4.9 | Phoenix bought Anawa for 0.53M |
(Switzerland) | International | Phoenix shares (US$4.9M, con- | |||
Life Sciences Inc. | verted at a rate of C$1.45/US$1) | ||||
(Canada) | |||||
Apollon Inc.* | Wyeth-Lederle | — | 5/98 | ND | ND |
Vaccines (unit of | |||||
Wyeth-Ayerst Lab- | |||||
oratories, a division | |||||
of American Home | |||||
Products Corp.; | |||||
NYSE:AHP) | |||||
Aptein Inc.* | Cambridge Anti- | 6/98 | 7/98 | $11 | Cambridge Antibody issued 1.29M |
body Technology | shares of its stock ($6M) on clos- | ||||
Group plc (U.K.) | ing and the balance ($5M in stock) | ||||
on issuance of European patent on | |||||
Aptein's polysome display tech- | |||||
nology | |||||
Biomira Diagnostics | Centocor | 4/98 | 5/98 | $7 | Biomira sold the operations of its |
Inc. (wholly owned | Diagnostics | diagnostics subsidiary that concern | |||
subsidiary of Biomira | (subsidiary of | Truquant blood test kits for breast, | |||
Inc.; Canada) | Centocor Inc.) | ovarian and gastrointestinal cancer | |||
to Centocor Diagnostics; Biomira | |||||
could get maximum of US$7M for | |||||
the sale plus licensing royalties on | |||||
antibodies and antigens for use in | |||||
in vitro diagnostics; operations at | |||||
Biomira Diagnostics will cease by | |||||
8/98; Biomira did not sell its hep- | |||||
atitis test kit to Centocor | |||||
BioSignal Inc.* | Packard | — | 7/98 | $8.5 | Packard already owned a 19% |
(Canada) | BioScience Co.* | stake in BioSignal; it paid $8.5M | |||
for the remaining 81% | |||||
Imperial Cancer | Antisoma plc* | — | 5/98 | ND | Antisoma bought out Imperial |
Research Technology's | (U.K.) | Cancer's share in the joint venture | |||
interest in joint venture | company Cancer Therapeutics and | ||||
Cancer Therapeutics | obtained rights to all products and | ||||
Ltd. (U.K.) | technology formerly owned by the | ||||
joint venture; in exchange, Imper- | |||||
ial Cancer Research Technology | |||||
got 5.7M newly issued shares of | |||||
Antisoma (for a 13.6% equity | |||||
stake) and gets royalties on product | |||||
sales | |||||
Carnick Laboratories | Elan Corp. plc | 4/98 | 6/98 | $150 | Elan acquired Carnick for $150M |
Inc. (subsidiary of | (Ireland) | in combination of cash and a | |||
GWC Health Inc.*) | promissory note; Carnick will be- | ||||
come part of Elan Pharmaceuticals | |||||
Chemical Design | Oxford Molecular | — | 5/98 | ND | ND |
Holdings plc | Group plc (U.K.) | ||||
(AIM:CHD; U.K.) | |||||
Hoechst AG's interest | Chiron Corp. | — | 4/98 | $115.5 | Chiron had acquired a 49% stake |
in joint venture Chiron | in the human vaccines business of | ||||
Behring GmbH & Co. | Hoechst subsidiary Behringwerke | ||||
(Germany) | AG in 7/96 (for $115M); Chiron | ||||
has now paid $115.5M for the | |||||
remaining 51% stake | |||||
ClinData International | Quintiles Trans- | — | 6/98 | ND | Quintiles acquired both com- |
Pty Ltd. (South Africa) | national Corp. | panies in exchange for Quintiles | |||
and Cardiac Alert (U.K.) | stock in separate transactions | ||||
Gene/Networks* | Warner-Lambert | — | 5/98 | ND | ND |
Co. (NYSE:WLA) | |||||
Research products | Techne Corp. | 6/98 | 7/98 | $65.5 | Techne bought Genzyme's |
business of | (NASDAQ:TECH) | research products business for | |||
Genzyme Corp. | $65.5M ($24.8M in cash, $17M | ||||
in Techne stock [0.987M shares at | |||||
$17.22 each] and royalties of | |||||
$23.7M on Techne's biotech group | |||||
product sales over next 5 years); | |||||
Genzyme has retained its in vitro | |||||
diagnostics products business | |||||
HumaTech | ProCyte Corp. | — | 4/98 | $3 | ProCyte acquired HumaTech for |
Laboratories* | $3M total ($1.1M cash and 1.1M | ||||
shares ProCyte common stock | |||||
valued at $1.5M) | |||||
Ibah Inc. | Omnicare Inc. | 3/98 | 6/98 | $169 | Ibah stockholders received 0.1638 |
(NYSE:OCR) | share Omnicare for each Ibah share | ||||
for total purchase price of $169M | |||||
Institute for | Phoenix | — | 5/98 | ND | Phoenix acquired certain assets of |
Pharmacodynamic | International | the institute for cash and future | |||
Research* (Germany) | Life Sciences Inc. | payments based on an earn-out | |||
(Canada) | formula; details ND | ||||
International Murex | Abbott Labor- | 3/98 | 7/98 | $234 | Abbott launched a tender offer in |
Technologies Corp. | atories (NYSE:ABT) | 3/98 to acquire 100% of the out- | |||
(NASDAQ:MURXF; | standing shares of International | ||||
Canada) | Murex for $13.00 per share (a 22% | ||||
premium to market); it received | |||||
96% (or 16.2M shares) of those | |||||
(on fully diluted basis) through the | |||||
tender offer and subsequently bought | |||||
the rest (also at $13.00 per share) in | |||||
a compulsory acquisition process | |||||
Matrigen Inc.* | Prizm Pharma- | — | 5/98 | ND | The companies combined their |
ceuticals Inc. | core technologies via merger to | ||||
form a new company, Selective | |||||
Genetics Inc.; details ND | |||||
MGA Software Inc.* | Pharsight Corp.* | 4/98 | 6/98 | ND | Pharsight acquired the pharmaceuti- |
cal assets of MGA; further details ND | |||||
Molecular | Pharmacopeia Inc. | 2/98 | 6/98 | $130 | Pharmacopeia acquired all out- |
Simulations Inc.* | standing stock of Molecular Simu- | ||||
lations for 7.1M newly issued | |||||
shares Pharmacopeia common | |||||
stock; it will also convert Mole- | |||||
cular Simulation's outstanding | |||||
options into Pharmacopeia options, | |||||
which may result in issuance of | |||||
1.4M more new Pharmacopeia shares | |||||
Northwest | Neurocrine | 3/98 | 6/98 | $4.2 | Neurocrine paid a total of $4.2M |
Neurologic Inc.* | Biosciences Inc. | by issuing new shares of its | |||
common stock to acquire North- | |||||
west Neurologic | |||||
Research products | Intergen Inc. | 6/98 | 6/98 | $3.2 | Oncor sold its research products |
division of Oncor Inc. | division to Intergen for $3.2M ($3M in | ||||
cash on closing and the rest as sched- | |||||
uled payments over next 2 years) | |||||
PanGenetics BV* | Tanox | — | 4/98 | ND | Tanox acquired a majority stake in |
(the Netherlands) | Biosystems Inc.* | PanGenetics and has agreed to | |||
acquire the remaining stock under | |||||
certain conditions (details ND) | |||||
Precision | IGT Pharma Inc. | 3/98 | 4/98 | ND | IGT had held a 35% stake in Pre- |
Biochemicals Inc.* | (VSE:IGT; Canada) | cision Biochemicals since 7/97; it | |||
(Canada) | acquired the remaining 65% by | ||||
exchanging 0.48M shares of IGT | |||||
for the remaining shares of Pre- | |||||
cision Biochemicals | |||||
PharmaSciences | PowderJect | — | 4/98 | $1.6 | PowderJect acquired Pharma- |
Inc.'s interest in joint | Pharmaceuticals | Sciences' minority equity stake in | |||
venture Psiox Inc.* | plc (U.K.) | their joint venture Psiox for $1.6M | |||
(0.2M shares at 505p per share); | |||||
Psiox will change its name to | |||||
PowderJect Therapeutics Inc. | |||||
Rosys AG* | Qiagen NV | — | 5/98 | $15.8 | Qiagen acquired 100% of the out- |
(Switzerland) | (the Netherlands) | standing shares of Rosys in a | |||
stock exchange worth $15.8M | |||||
Somatogen Inc. | Baxter Inter- | 2/98 | 5/98 | $189 | Baxter paid Somatogen share- |
national Inc. | holders $9/share in Baxter stock | ||||
(NYSE:BAX) | for all 21M shares outstanding; | ||||
Baxter will also make deferred | |||||
cash payments of up to $2/share | |||||
($42M total) based on 5% of sales | |||||
of certain future-generation prod- | |||||
ucts through 12/31/07; each share | |||||
Somatogen common stock was | |||||
converted into the right to receive | |||||
0.1685 share of Baxter common | |||||
stock and 1 contingent right | |||||
Transcell | Intercardia Inc. | 11/97 | 5/98 | $14.2 | The companies signed a letter of |
Technologies Inc.* | (subsidiary of | intent in 11/97 and a definitive | |||
(majority-owned sub- | Interneuron Phar- | merger agreement in 3/98; Inter- | |||
sidiary of Interneuron | maceuticals Inc.) | cardia acquired the capital stock | |||
Pharmaceuticals Inc.) | of Transcell plus related technol- | ||||
ogy rights held by Interneuron in | |||||
exchange for $14.2M in Intercar- | |||||
dia stock; Transcell's outstanding | |||||
options and warrants will be con- | |||||
verted into options and warrants | |||||
good for a total of 0.26M shares of | |||||
Intercardia stock; the outstanding | |||||
Transcell stock will be converted | |||||
into right to receive Intercardia | |||||
stock in 3 installments (the 1st to | |||||
be made in connection with clos- | |||||
ing; the others at 15 and 21 months) | |||||
with total combined value of $11.2M; | |||||
Intercardia paid $3M in stock (0.175M | |||||
shares) to Interneuron for technology | |||||
rights; postmerger, Interneuron owns | |||||
62% of Intercardia's stock | |||||
VacTex Inc.* | Aquila Biopharma- | — | 4/98 | $8.2 | Aquila acquired 100% of outstand- |
ceuticals Inc. | ing shares of VacTex in exchange | ||||
for 1.15M newly issued shares of | |||||
Aquila stock plus a note for $1.3M | |||||
(including accrued interest at 7%; | |||||
redeemable after 4/13/99); the | |||||
acquisition is valued at $8.2M | |||||
Viatech Imaging LLC* | Cognetix Inc.* | — | 7/98 | ND | ND |
II. PENDING MERGERS AND ACQUISITIONS | |||||
Gen Trak Inc.* | Genetic Vectors | 5/98 | — | ND | Genetic Vectors will acquire 100% |
Inc. (OTC Bulletin | of Gen Trak's stock; definitive | ||||
Board:GVEC) | merger agreement still pending | ||||
GenQuest Inc.* | Corixa Corp. | 6/98 | 8/98E | $11.8 | Corixa already holds a 17% stake |
in GenQuest and will buy the rest | |||||
for $11.8M ($4.5M in cash and | |||||
the remainder in Corixa common | |||||
stock) | |||||
ImmunoTherapy | Antivirals Inc. | 11/97 | ND | $13.9 | According to the letter of intent |
Corp.* | (11/97), Antivirals was to buy | ||||
ImmunoTherapy for $24M in | |||||
stock and warrants; however, the | |||||
definitive agreement (2/98) states | |||||
that Antivirals will acquire Immu- | |||||
noTherapy for 2.1M shares | |||||
(at $6.625 each on 2/3/98, for total | |||||
of $13.9M) and 2.1M warrants; | |||||
shareholders from both compan- | |||||
ies still need to approve merger, | |||||
but Antivirals has already changed | |||||
its company name to AVI Bio- | |||||
Pharma to reflect the merger | |||||
Imtix (division of | SangStat Medical | 4/98 | YE98E | $33 | SangStat will acquire Imtix for |
Pasteur Merieux | Corp. | $33M in cash ($12M upfront at | |||
Connaught, a mem- | closing and deferred cash pay- | ||||
ber of the Rhone- | ments of $21M over 5 years); Pas- | ||||
Poulenc Group; | teur Merieux gets royalties on sale | ||||
France) | of Imtix products; closing subject | ||||
to regulatory clearance | |||||
Inflammatics Inc.* | Viragen Inc. | 1/98 | — | ND | Companies will form a strategic |
alliance; Viragen could acquire | |||||
up to 80% of Inflammatics upon | |||||
completion of current Phase I/II | |||||
trials and future Phase III trials of | |||||
LeukoVAX (human white blood | |||||
cell-derived drug for treating | |||||
rheumatoid arthritis) | |||||
Life Technologies | Dexter Corp. | 7/98 | — | $240 | Dexter will acquire the 48% of |
Inc. | (NYSE:DEX) | Life Technologies it doesn't already | |||
own (11.3M shares) for $37.00 cash | |||||
per share (18% premium to market); | |||||
transaction subject to approval by | |||||
Life Technologies' board of directors | |||||
Neurex Corp. | Elan Corp. plc | 4/98 | 3Q:98E | $740 | Elan will acquire all of Neurex's out- |
(Ireland) | standing shares (23.3M) for $31.81 | ||||
per share; each share Neurex will be | |||||
exchanged for 0.51 Elan American | |||||
Depositary Share; Neurex will become | |||||
part of Elan Pharmaceuticals; antitrust | |||||
considerations cleared in U.S. and Ire- | |||||
land 6/98; transaction still requires | |||||
approval of Neurex shareholders | |||||
OncorMed Inc. | Gene Logic Inc. | 7/98 | 4Q:98E | $38 | Gene Logic will acquire 100% of |
OncorMed's outstanding stock for | |||||
a maximum of 4.85M shares of | |||||
Gene Logic stock (ratio of 0.48:1; | |||||
actual number could vary depending | |||||
on trading price at closing); Gene Logic | |||||
will also assume outstanding warrants | |||||
for OncorMed stock; Gene Logic loaned | |||||
OncorMed $1.5M for operations; trans- | |||||
action subject to approval of both | |||||
companies' shareholders | |||||
OST Developpement | Osteotech Inc. | 7/98 | 3/99E | $1.5 | Osteotech will acquire a majority |
SA* (subsidiary of | interest in OST in 2 steps; in 6/98, | ||||
Transphyto SA, France) | it acquired a 5% stake; it will | ||||
acquire an additional 85% stake | |||||
no later than 3/99 contingent on | |||||
certain milestones; total cost will | |||||
be $1.5M (FFr9M); the agreement | |||||
provides for Osteotech's purchase | |||||
of the remaining 10% in the future | |||||
Penederm Inc. | Mylan Laboratories | 6/98 | YE98E | $205 | Mylan will acquire Penederm for |
Inc. (NYSE:MYL) | stock; Penederm shareholders get | ||||
0.68 share Mylan for each share | |||||
Penederm (valued at $21.89 per | |||||
share to Penederm holders); trans- | |||||
action subject to approval of Pene- | |||||
derm shareholders | |||||
Proceutics Inc. | Oread Inc.* | 2/98 | — | ND | Proceutics will transfer its person- |
(wholly owned sub- | nel, equipment and client contracts | ||||
sidiary of CytRx Corp.) | to Oread; Proceutics will retain its | ||||
real estate assets (but is negotiating | |||||
their sale independently but con- | |||||
currently) | |||||
Seragen Inc. (OTC | Ligand Pharma- | 5/98 | 8/98E | $67 | Ligand will acquire Seragen for |
Bulletin Board:SRGN) | ceuticals Inc. | $67M in cash and stock, of which | |||
$37M is contingent on FDA | |||||
approval of Seragen's cancer drug | |||||
Ontak (for cutaneous T-cell | |||||
lymphoma); Ligand will pay $30M | |||||
on closing ($4M in cash and $26M | |||||
in Ligand stock [1.86M shares at | |||||
$13.99 each]); Ligand will pay an | |||||
additional $37M in cash and/or | |||||
Ligand stock 6 months after FDA | |||||
approval or not at all if FDA approv- | |||||
al hasn't occurred within 2 years; | |||||
Ligand also will acquire assets of | |||||
Marathon Biopharmaceuticals LLC | |||||
(which manufactures Seragen drugs) | |||||
for $5M, with another $3M 6 months | |||||
after FDA approval of Ontak (both | |||||
payments in cash and/or stock); Eli | |||||
Lilly and Co. will assign to Ligand its | |||||
rights to Ontak; Lilly can get up to | |||||
$10M in milestones; agreement subject | |||||
to approval by regulatory author- | |||||
ities and Seragen shareholders | |||||
Tseng Labs Inc. | Cell Pathways Inc.* | 6/98 | 10/98E | $177 | This is a reverse merger, by which |
(NASDAQ:TSNG) | Cell Pathways will gain a Nas- | ||||
daq listing (Tseng has no opera- | |||||
tions currently); Cell Pathways | |||||
will acquire and merge with Tseng | |||||
in exchange for 5.5M Cell Path- | |||||
ways shares; former Tseng share- | |||||
holders will own 23% of new com- | |||||
pany; transaction subject to | |||||
approval by SEC and shareholders | |||||
of both companies | |||||
Vascular Genomics | Corvas | 7/97 | 7/00E | $13-$20 | Corvas has 3-year option to acquire |
Inc.* | International Inc. | Vascular Genomics; it will make the | |||
purchase with new shares of Corvas | |||||
stock from $13M-$20M depending on | |||||
when the option is exercised; the | |||||
option will be automatically triggered | |||||
if Corvas enters into a partnering | |||||
agreement having an equal value; dur- | |||||
ing option period, Corvas has exclu- | |||||
sive rights to patented vascular tar- | |||||
geting technology and will fund | |||||
R&D at $1M/year; if Corvas | |||||
elects not to exercise option, | |||||
Vascular Genomics may require | |||||
it to buy 20% of its stock for | |||||
$3.96M in Corvas stock | |||||
Virus Research | T Cell Sciences | 5/98 | 3Q:98E | $150 | T Cell Sciences will acquire Virus |
Institute Inc. | Inc. | Research by issuing 1.55 shares of | |||
T Cell stock and 0.2 warrant for | |||||
each share Virus Research stock; | |||||
each warrant gives right to buy 1 | |||||
share T Cell for $6.00 for 5 years | |||||
after merger closes; the new com- | |||||
bined company will be called | |||||
Avant Immunotherapeutics Inc.; | |||||
transaction subject to shareholder | |||||
and regulatory approvals | |||||
III. TERMINATED MERGERS AND ACQUISITIONS | |||||
BioStar Inc.* | Cortech Inc. | 12/97 | Terminated | $18.7 | Cortech was to issue 28.5M new |
5/98 | shares in exchange for all equity | ||||
interests in BioStar in this reverse | |||||
merger; either party had the option | |||||
of terminating negotiations if it | |||||
appeared that the merger could not | |||||
be completed by 5/31/98; this situ- | |||||
ation occurred, so the parties ter- | |||||
minated discussions by mutual | |||||
agreement | |||||
NOTES: | |||||
# This chart is intended to include not only mergers and acquisitions of entire businesses, but also of divisions or subsidiaries of those businesses, where appropriate. It does not include acquisitions of single products or of manufacturing facilities and plants. It does not include mergers and acquisitions in the area of agricultural biotechnology (which are treated separately in BioWorld Financial Watch). The information on the chart encompasses the period from 3/11/98 - 7/24/98. For those deals that are pending, and for which the acquiring company is issuing stock, the value of the transaction has been calculated based on the closing price on the day of the first announcement. For those deals that have been completed, and for which the acquiring company is issuing stock, the final value has been calculated based on the closing price on the date that the merger's completion was announced. | |||||
E = Estimated date, dependent on approval of regulatory authorities and shareholders of one or all companies involved in the transaction; AIM = Alternative Investment Market; ND = Not disclosed, reported and/or available; VSE = Vancouver Stock Exchange | |||||
* Private companies are indicated with an asterisk. | |||||
** Unless otherwise noted, the trading symbols for public biotechnology companies can be found by referring to the BioWorld Stock Report For Public Biotechnology Companies on pp. 12-13. |